Have a look at our latest update of German price negotiations for drugs that went through the AMNOG benefit assessment. The mean price decrease after negotiations was 28 % for all analysed products, 23 % for orphan drugs and 30 % for non-orphan drugs.
If you have any further questions or suggestions, please feel free to contact our team of experts.
Figure: Price decrease after negotiations for drugs that underwent AMNOG benefit assessments between 2011 – 2022. The price loss is shown as percent difference between the launch price and the final reimbursement price. Prices after deduction of taxes and mandatory rebates were used for the calculation. Boxes indicate the 25th and 75th percentile, the median is marked by the horizontal line, and the mean by X. The mean values are labelled. Source: Lauertaxe, August 2022; www.g-ba.de 2022.